Navigation Links
Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent
Date:1/29/2008

CALGARY, Jan. 29 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") has been granted Canadian Patent 2,408,251 entitled "Clearance of Neoplastic Cells from Mixed Cellular Compositions using Viruses." The claims describe methods of selectively removing cancer cells ex vivo from blood stem cells and other organs using various viruses including modified vaccinia viruses, herpes simplex viruses, parapoxviruses and adenoviruses.

"This patent broadens coverage in the area of using other modified oncolytic viruses to purge contaminating cancer cells from stem cell preparations used for transplants," said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics please visit http://www.oncolyticsbiotech.com.

This news release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including among others, the Company's belief as to the importance of the issuance of this patent, the safety and efficacy of the reovirus, the Company's expectations as to the potential applications of the patented technology and other statements relating to anticipated developments in the Company's business and technologies, involve known and unknown risks and uncertainties that could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN(R)
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
2. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
3. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
4. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
5. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
6. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
7. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
8. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
9. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
10. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
11. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... electrons, but one of the most promising technologies for ... on light (photons) instead of electrons. First, it is ... single photons and control their direction. Researchers around the ... this control, but now scientists at the Niels Bohr ... photons emitted one at a time and in a ...
(Date:8/29/2014)... Pittcon is pleased to announce that ... Matsuda, Horiba Scientific, have organized a session on nanotechnology ... JASIS , Asia’s largest analytical and scientific instruments show, ... Japan. , The four speakers in this U.S. ... Molecules to Single Cells” will present their use of ...
(Date:8/29/2014)... 29, 2014 Three Lawrence Livermore ... Hydrogen Production R&D Award for their ... water using sunlight. , Shared with collaborators from ... University of Nevada, Las Vegas (UNLV), the award ... of photoelectrochemical solar-hydrogen production and corrosion processes. , ...
(Date:8/29/2014)... MA, San Antonio, TX (PRWEB) August 29, 2014 ... ISO 9001:2008 and ISO 13485:2003 certified, GAMP® 5 ... has been awarded an international Phase II clinical ... with non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic ... including, but not limited to, protocol and charter ...
Breaking Biology Technology:Breakthrough in light sources for new quantum technology 2Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2Livermore Team Awarded for Hydrogen Production Research 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2
... One of the IT industry news rags was making a ... in radio frequency ID tag manufacture. Almost as a throw-away ... rates of up to 20 percent. , ,The tag ... even embedded tags being crunched when the paper was rolled ...
... Michigan in Ann Arbor will create a $10.5 million ... at bolstering the university's position in the science. , ,For ... lines from Wisconsin's WiCell Research Institute , among others. ... by the U-M Medical School, the Life Sciences Institute and ...
... CHICAGO -- As more organizations look at what ... with SEC issues, an area that has come under ... Risk management and corporate governance issues have become issues ... , ,The Sarbanes-Oxley Act (SOX) has become a reason ...
Cached Biology Technology:The more things change ... 2The more things change ... 3University of Michigan plans major stem cell research center 2University of Michigan plans major stem cell research center 3Sarbox necessitating ECM software, but beware of `best practices' 2Sarbox necessitating ECM software, but beware of `best practices' 3
(Date:8/29/2014)... Scientists at the Barshop Institute for Longevity and ... the UT Health Science Center at San Antonio, have ... the longest-lived rodent, the naked mole rat. , ... naked mole rats protects and alters the activity of ... proteins. , The factor also protects proteasome function in ...
(Date:8/29/2014)... Ebola researcher from the University of Texas Medical Branch at ... three monoclonal antibodies can completely protect monkeys against a lethal ... at a time when the disease is severe. , Thomas ... for Nature discussing advances in Ebola treatment research. ... among the most deadly of pathogens, with fatality rates of ...
(Date:8/29/2014)... of connections in transcription factor networks (TFNs) to evaluate ... published in PLOS Computational Biology in August. ... to a network,s resilience against mutations. , "In ... TFN models has a greater effect on robustness than ... said Dov A. Pechenick, PhD, lead author and former ...
Breaking Biology News(10 mins):Factor in naked mole rat's cells enhances protein integrity 2Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2Assortativity signatures of transcription factor networks contribute to robustness 2
... CHAMPAIGN, Ill. University of Illinois researchers are using ... weightiest questions in biology the relationship between cell mass ... computer engineering and bioengineering professor Rashid Bashir, published its results ... the National Academy of Sciences . "It,s merging micro-scale ...
... , LA JOLLA, CA-Fisetin, a naturally occurring compound ... slows the onset of motor problems and delays ... to researchers at the Salk Institute for Biological ... of Human Molecular Genetics , sets the ...
... ovarian cancer but new research from the Centenary Institute has ... new way that can break the resistance mechanism. Published ... (FTY720) had a potent effect in human ovarian cancer cells, ... chemotherapeutic drug currently available for the treatment of ovarian cancer. ...
Cached Biology News:Microsensors offer first look at whether cell mass affects growth rate 2Natural compound shows promise against Huntington's disease 2Natural compound shows promise against Huntington's disease 3New treatment to overpower drug resistance in ovarian cancer 2
... EC570-90 is a compact, lightweight, high current power ... or 2500 milliamps. It is an excellent choice ... gels. It is also ideal for all types ... be set to automatically end a run and ...
... a highly purified preparation qualified to specifically ... The preparation is functionally tested for activity ... detectable contaminating proteases. Prepared from human plasma ... to be negative for HBsAg and for ...
Acetate Plate Sealers 100/Box...
... Buffer is a concentrated formulation of a ... capillary action technology, as well as for ... with David Brigati M.D., Department of Pathology, ... buffer is recommended for all the rinsing ...
Biology Products: